1998
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models
Herbst R, Takeuchi H, Teicher B. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemotherapy And Pharmacology 1998, 41: 497-504. PMID: 9554595, DOI: 10.1007/s002800050773.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow CellsCarboplatinCarcinoma, Lewis LungCell SurvivalColony-Forming Units AssayCyclohexanesDrug SynergismDrug Therapy, CombinationFemaleMaleMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMice, Inbred C57BLMinocyclineNeovascularization, PathologicO-(Chloroacetylcarbamoyl)fumagillolPaclitaxelSesquiterpenesConceptsTNP-470/minocyclineEMT-6 mammary carcinomaBone marrow CFU-GMLewis lung carcinomaMarrow CFU-GMEMT-6 tumor cellsLung carcinomaMammary carcinomaCFU-GMNormal tissuesTumor cellsHigh-dose paclitaxelCell lung cancerCombination of paclitaxelToxicity of carboplatinEfficacy of chemotherapyTumor growth delayBreast carcinoma modelCytotoxicity of carboplatinEarly time pointsAgent regimenAntiangiogenic regimenCarboplatin administrationLung metastasesCell lungAcute in vivo resistance in high-dose therapy.
Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E. Acute in vivo resistance in high-dose therapy. Clinical Cancer Research 1998, 4: 483-91. PMID: 9516940.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCyclophosphamideDisease Models, AnimalDose-Response Relationship, DrugDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleMammary Neoplasms, ExperimentalMelphalanMiceMice, Inbred BALB CNeoplasm TransplantationPaclitaxelThiotepaConceptsTumor growth delayAdditive tumor growth delayHigh-dose cyclophosphamideHigh-dose melphalanGrowth delaySecond highest doseHigh doseSequential high-dose chemotherapyTumor cell survival assayEMT-6 mammary carcinomaTumor growth delay studiesBone marrow colony-forming unitsHigh-dose therapyMarrow colony-forming unitsHigh-dose chemotherapyBone marrow CFU-GMHigh-dose treatmentGrowth delay studiesTumor-bearing miceMarrow CFU-GMSolid tumor modelsCell survival assayCombination regimensMammary carcinomaCyclophosphamidePotential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Research 1998, 18: 2567-73. PMID: 9703911.Peer-Reviewed Original ResearchMeSH Keywords9,10-Dimethyl-1,2-benzanthraceneAnimalsAnticarcinogenic AgentsAntineoplastic AgentsCarcinoma, Lewis LungCell DivisionCholestanolsCisplatinCombined Modality TherapyCyclophosphamideDoxorubicinDrug Therapy, CombinationFemaleFluorouracilMammary Neoplasms, ExperimentalMiceOxygenOxygen ConsumptionPaclitaxelPartial PressureRatsRats, Inbred F344ConceptsLewis lung carcinomaTumor growth delayPost-tumor implantationLung carcinomaGrowth delayLung metastasesTumor implantationMammary carcinomaTumor oxygenationDay 4Chemotherapeutic agentsPrimary Lewis lung tumorMurine Lewis lung carcinomaDaily subcutaneous injectionsLewis lung tumorTumor-bearing animalsModest effectCombination therapyContinuous infusionCytotoxic therapySystemic diseaseSubcutaneous injectionLung tumorsAntiangiogenic agentsHypoxic fraction
1997
PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher B, Ara G, Herbst R, Takeuchi H, Keyes S, Northey D. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. In Vivo 1997, 11: 301-11. PMID: 9292296.Peer-Reviewed Original ResearchConceptsPEG-hemoglobinTumor growth delayMammary carcinomaTumor cell killingSolid tumorsTumor oxygenationGrowth delayDose of chemotherapyEMT-6 murine mammary carcinomaBone marrow CFU-GMEfficacy of chemotherapyEMT-6 tumorsMurine mammary carcinomaTumor-bearing miceCFU-GM survivalMarrow CFU-GMCell killingOxygen delivery agentEMT-6 tumor-bearing miceChemotherapy administrationLung metastasesMultiple dosesSingle dosesChemotherapyCFU-GM
1996
Lisofylline as a modifier of radiation therapy.
Wong J, Ara G, Keyes S, Herbst R, Coleman C, Teicher B. Lisofylline as a modifier of radiation therapy. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 1996, 8: 513-8. PMID: 9160355.Peer-Reviewed Original ResearchConceptsEMT-6 cellsHypoxic EMT-6 cellsGy/minDose rate radiationTumor growth delay assayRate radiationEMT-6 murine mammary carcinomaSingle-dose radiationGrowth delay assayMurine mammary carcinomaHigh dose rate radiationLow dose rate radiationGamma radiation therapyRadiation survival curvesTumor cell survivalContinuous infusionMultiple dosesMammary carcinomaRadiation therapyPentoxifyllineLisofyllineRadiation settingsSurvival curvesDose radiationRadiation exposure